Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
Executive Summary
In VC deals, Magenta raised $50m, licensed a Novartis asset and engaged an important partner. Seven public companies revealed financial transactions totaling $947.4m, including Achaogen's $20.5m from the Gates Foundation. Also, OncoMed, Regulus and Depomed provided restructuring updates.
You may also be interested in...
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
IPO Update: New Offerings Outperform As September Ends With Biopharma Trifecta
There have been 29 IPOs in the US through the third quarter of 2017 with an average return of 35.2%, including three offerings on the same day – Deciphera, Nightstar and NuCana – near the end of September.
Finance Watch: Bicycle Spins Toward Clinic With $52m Round; Stock Spikes Spur Offerings
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.